Von Wasielewski R, Mengel M, Fischer R, Hansmann M, Hübner K, Tesch F, Paulus H, et al. Classical Hodgkin’s disease: clinical impact of the immunophenotype. am j Pathol. 1997;1123–30.
2.
The immunohistochemistry of Hodgkin’s disease. semin diagn Pathol. 1992;265–71.
3.
Herbst H, Niedobitek E, G, Ls Y, Brooks L, Müller-Lantzsch N, et al. distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin’s disease. Blood. 1992;484–91.
4.
Gulley M, Glaser Sl, Craig F, Borowitz M, Mann. Guidelines for interpreting EBEr in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Clin Pathol. 2002;259–67.
5.
Keegan T, Glaser Sl C, Ca, Gulley M, Craig F, Mann. Epstein-Barr virus as a marker of survival after Hodgkin’s lymphoma: a population -based study. Clin Oncol. 2005;(23):7604–13.
6.
Kamel O, Ra W. Leu 7 (Cd57) reactivity distinguishes nodular lymphocyte predominance Hodgkin’s disease from nodular sclerosing Hodgkin’s disease, T-cell-rich-B-cell lymphoma and follicular lymphoma. am j Pathol. 1993;541–6.
7.
Jaffe Es, Hematopathology, Philadelphia P, Elsevier. 2011;
8.
Connors jM. state of the art therapeutics: Hodgkin’s lymphoma. Clin Oncology. 2005;(23):6400–8.
9.
Diehl V. New strategies for the treatment of advanced stage Hodgkin’s lymphoma. Hematology/ Oncology. 2007;(21):897–914.
10.
David Ka, Mauro L. Evens aM. . relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options. Curr Treat Options Oncol. 2007;(8):352–74.
11.
Steidl C, Lee T, Farinha P, Han G, Nayar T. Tumor-associated Macrophages and survival in Classic Hodgkin’s Lymphoma. N Engl j Med. 2010;(10):875–85.
12.
Tzankov M, Ms. dirnhofer s. refined prognostic role of Cd68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology. 2010;301–8.
13.
Farinha P. Lymphoma associated macrophages predict survival in uniformly treated patients with classical Hl. 1257;
14.
Jakovic Lr M, Bs. Perunicic jovanovic Md, Bogdanovic ad, andjelic BM, Bumbasirevic VZ. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma. 2011;(10).
15.
Meier C, Hirschmann P, Went P. Pileri sa, dirnhofer s. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin lymphoma. Haematologica. 2008;193–200.
16.
Kelley T, Pohlman B, Elson P, Hsi E. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independet of bcl-2 and MaL expression. am j Clin Pathol. 2007;958–65.
17.
Costa. Toward a personalized treatment of Hodgkin’s disease. N Engl j Med. 2010;942–3.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
